Development and validation of high-performance liquid chromatographic method for quantification of Irinotecan and its active metabolite SN-38 in colon tumor bearing NOD/SCID mice plasma samples: application to pharmacokinetic study

• Autorzy: Taneja Neetika , Gota Vikram , Gurjar Murari , Singh Kamalinder K.

Identyfikatory

DOI

10.1556/1326.2018.00370

• Języki publikacji: EN

Abstrakty

EN

Irinotecan (IRT) is an antineoplastic agent widely used in the treatment of various cancers primarily in colorectal cancer. A new, simple and sensitive high-performance liquid chromatography (HPLC) method coupled with fluorescence detector was developed and validated to quantify IRT and its active metabolite SN38 in the plasma of non-obese diabetic/severe combined immune-deficient mice (NOD/SCID) mice bearing colon tumor. The plasma samples were extracted by precipitation method using acetonitrile with 0.1% formic acid. The chromatographic separation was achieved using mobile phase consisted of water and acetonitrile (57:43 v/v) pH 3 at the flow rate of 0.8 mL/min in C18 column (internal diameter, 250 × 4.6 mm; pore size, 5 μm). The method was validated according to the bioanalytical guidelines defined by Food and Drug Administration (FDA) and European Medicine Agency (EMA). A regression (R2) value of 0.999 and 0.997 for IRT and SN38 suggested the good linearity in the range of 0.1–10 μg/mL and 5–500 ng/mL, respectively. The calculated lower limit of quantification (LLOQ) and limit of detection (LOD) for IRT were 0.1 and 0.065 μg/mL, respectively. However, for SN38, LLOQ and LOD were 5 and 2 ng/mL, respectively. The intra-day and inter-day variations (coefficient of variance; % CV) observed during the validation were found to be within the set limit of 15%. Both accuracy and percentage recovery analyzed and calculated from the quality control samples were in the between the defined range of 85–115%. Plasma samples were found to be stable when stored at room temperature for 2 h, after 2 freeze–thaw cycles and at −80 °C for 2 months. The developed method was successfully applied to study the plasma elimination profile of IRT in NOD/SCID mice with tumor. The results from plasma concentration time profile and pharmacokinetic parameter analyzed suggested the rapid elimination of IRT and SN38 from the plasma of NOD/SCID mice.

Słowa kluczowe

EN

Irinotecan; SN-38; HPLC; pharmacokinetic; validation; linearity; precision

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2019
• Tom: Vol. 31, no. 3
• Strony: 166--172
• Opis fizyczny: Bibliogr. 45 poz., rys., tab.

Twórcy

autor

Taneja Neetika

• C. U. Shah College of Pharmacy, S.N. D. T. Women's University, Santacruz (W), Mumbai 400049 , India

autor

Gota Vikram

• Department of Clinical Pharmacology, Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, India

autor

Gurjar Murari

• Department of Clinical Pharmacology, Advanced Centre for Treatment, Research and Education In Cancer, Navi Mumbai, India

autor

Singh Kamalinder K.

• School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, PR1 2HE, United Kingdom

Bibliografia

• [1] Nirmala, M. J.; Samu deeswari, A.; Sankar, P. D. Research in Plant Biology 2011, 1.
• [2] Van Cutsem, E.; Köhne, C.-H.; Láng, I.; Folprecht, G.; Nowacki, M. P.; Cascinu, S.; Shchepotin, I.; Maurel, J.; Cunningham, D.; Tejpar, S. J. Clin. Oncol. 2011, 29, 2011–2019.
• [3] Douillard, J.; Cunningham, D.; Roth, A.; Navarro, M.; James, R.; Karasek, P.; Jandik, P.; Iveson, T.; Carmichael, J.; Alakl, M. The Lancet 2000, 355, 1041–1047.
• [4] Rosen L. S. Oncology 1998, 12, 103–109.
• [5] Vredenburgh, J. J.; Desjardins, A.; Herndon, J. E.; Marcello, J.; Reardon, D. A.; Quinn, J. A.; Rich, J. N.; Sathornsumetee, S.; Gururangan, S.; Sampson, J. J. Clin. Oncol. 2007, 25, 4722–4729.
• [6] Liu, L. F.; Desai, S. D.; LI, T. K.; Mao, Y.; Sun, M.; SIM, S. P. Ann. N. Y. Acad. Sci. 2000, 922, 1–10.
• [7] Rivory, L. P.; Bowles, M. R.; Robert, J.; Pond, S. M. Biochem. Pharmacol. 1996, 52, 1103–1111.
• [8] Dodds, H. M.; Haaz, M.-C.; Riou, J.-F.; Robert, J.; Rivory, L. P. J. Pharmacol. Exp. 1998, 286, 578–583.
• [9] Humerickhouse, R.; Lohrbach, K.; Li, L.; Bosron, W. F.; Dolan, M. E. Cancer Res. 2000, 60, 1189–1192.
• [10] Trifan, O. C.; Durham, W. F.; Salazar, V. S.; Horton, J.; Levine, B. D.; Zweifel, B. S.; Davis, T. W.; Masferrer, J. L. Cancer Res. 2002, 62, 5778–5784.
• [11] Cunningham, D.; Pyrhönen, S.; James, R. D.; Punt, C. J.; Hickish, T. F.; Heikkila, R.; Johannesen, T. B.; Starkhammar, H.; Topham, C. A.; Awad, L. The Lancet 1998, 352, 1413–1418.
• [12] Drummond, D. C.; Noble, C. O.; Guo, Z.; Hong, K.; Park, J. W.; Kirpotin, D. B. Cancer Res. 2006, 66, 3271–3277.
• [13] Ramsay, E. C.; Anantha, M.; Zastre, J.; Meijs, M.; Zonderhuis, J.; Strutt, D.; Webb, M. S.; Waterhouse, D.; Bally, M. B. Clin. Cancer Res. 2008, 14, 1208–1217.
• [14] Paruchuri, R.; Trivedi, S.; Joshi, S. V.; Pavuluri, G.; Senthil Kumar, M. Int. J. Pharm. Chem. Biol. Sci. 2012, 2, 1–10.
• [15] Martins, S.; Tho, I.; Reimold, I.; Fricker, G.; Souto, E.; Ferreira, D.; Brandl, M. Int. J. Pharm. 2012, 439, 49–62.
• [16] Tamyurek, E.; Maltas, E.; Bas, S. Z.; Ozmen, M.; Yildiz, S. Int. J. Biol. Macromol. 2015, 73, 76–83.
• [17] Taneja, N.; Singh, K. K. Int. J. Pharm. 2018, 536, 82–94.
• [18] Passero Jr, F. C.; Grapsa, D.; Syrigos, K. N.; Saif, M. W. Expert Rev. 2016, 16, 697–703.
• [19] DiGiulio S. Oncology Times 2015.
• [20] Tian, X.; Nguyen, M.; Foote, H. P.; Caster, J. M.; Roche, K. C.; Peters, C. G.; Wu, P.; Jayaraman, L.; Garmey, E. G.; Tepper, J. E. Cancer Res. 2017, 77, 112–122.
• [21] Walsh, M. D.; Hanna, S. K.; Sen, J.; Rawal, S.; Cabral, C. B.; Yurkovetskiy, A. V.; Fram, R. J.; Lowinger, T. B.; Zamboni, W. C. Clin. Cancer Res. 2012, 18, 2591–2602.
• [22] Kerbel R. S. Cancer Biol. Ther. 2003, 2, 133–138.
• [23] Jung J. Toxicological Res. 2014, 30, 1–5.
• [24] Voskoglou-Nomikos, T.; Pater, J. L.; Seymour, L. Clin. Cancer Res. 2003, 9, 4227–4239.
• [25] Belizário J. E.Open Immunol. J. 2009, 2, 79–85.
• [26] Cheon, D.-J.; Orsulic, S. Annu. Rev. Pathol.: Mech. Dis. 2011, 6, 95–119.
• [27] Tariq, M.; Negi, L.; Talegaonkar, S.; Ahmad, F.; Iqbal, Z.; Khan, A. Indian J. Pharm. Sci. 2015, 77, 14.
• [28] Marangon, E.; Posocco, B.; Mazzega, E.; Toffoli, G. PloS One 2015, 10, e0118194.
• [29] Qi, P.; Zeng, T.; Wen, Z.; Liang, X.; Zhang, X. Food Chem. 2011, 125, 1462–1467.
• [30] Chen, X.; Peer, C.J.; Alfaro, R.; Tian, T.; Spencer, S. D.; Figg, W. D. J. Pharm. Biomed. Anal. 2012, 62, 140–148.
• [31] de Bruijn, P.; Verweij, J.; Loos, W. J.; Nooter, K.; Stoter, G.; Sparreboom, A. J. Chromatogr. B: Biomed. Sci. Appl. 1997, 698, 277–285.
• [32] Poujol, S.; Pinguet, F.; Malosse, F.; Astre, C.; Ychou, M.; Culine, S.; Bressolle, F. Clin. Chem. 2003, 49, 1900–1908.
• [33] Bansal, T.; Awasthi, A.; Jaggi, M.; Khar, R. K.; Talegaonkar, S. Talanta 2008, 76, 1015–1021.
• [34] Chollet, D. F.; Goumaz, L.; Renard, A.; Montay, G.; Vernillet, L.; Arnera, V.; Mazzo, D. J. J. Chromatogr. B: Biomed. Sci. Appl. 1998, 718, 163–175.
• [35] US Food and Drug Administration, FDA guidance for industry: bioanalytical method validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Rockville, MD, 2001.
• [36] Agency E. M. Guideline on bioanalytical method validation. Committee for Medicinal Products for Human Use (CHMP), 2011.
• [37] Al-Dgither, S.; Alvi, S. N.; Hammami, M. M. J. Pharm. Biomed. Anal. 2006, 41, 251–255.
• [38] Balaram, V. M.; Rao, J. V.; Ganesh, G. R. S. S.; Krishna, T. B. J. Chem. 2007, 4, 128–136.
• [39] Hu, Z.-P.; Yang, X.-X.; Chen, X.; Chan, E.; Duan, W.; Zhou, S.-F. J. Chromatogr. B 2007, 850, 575–580.
• [40] Sano, K.; Yoshikawa, M.; Hayasaka, S.; Satake, K.; Ikegami, Y.; Yoshida, H.; Ishikawa, T.; Sawada, S.; Tanabe, S. J. Chromatogr. B 2003, 795, 25–34.
• [41] Rivory, L. P.; Robert, J. J. Chromatogr. B: Biomed. Sci. Appl. 1994, 661, 133–141.
• [42] Sumiyoshi, H.; Fujiwara, Y.; Ohune, T.; Yamaoka, N.; Tamura, K.; Yamakido, M. J. Chromatogr. B: Biomed. Sci. Appl. 1995, 670, 309–316.
• [43] Messerer, C. L.; Ramsay, E.C.; Waterhouse, D.; Ng, R.; Simms, E.-M.; Harasym, N.; Tardi, P.; Mayer, L. D.; Bally, M. B. Clin. Cancer Res. 2004, 10, 6638–6649.
• [44] Shaikh, I. M.; Tan, K.-B.; Chaudhury, A.; Liu, Y.; Tan, B.-J.; Tan, B. M.; Chiu, G. N. J. Control. Release 2013, 172, 852–861.
• [45] Wu, M. H.; Yan, B.; Humerickhouse, R.; Dolan, M. E. Clin. Cancer Res. 2002, 8, 2696–2700.

Uwagi

PL

Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2019).